Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Waldenstrom J. Incipient myelomatosis or “essential” hyperglobulinema with fibrinogenopenia. A new syndrome? Acta Med Scand. 1944;117:216–22.
Waldenström J. Macroglobulinemia. A review. Haematologica 1986;71:437–40.
Vijay A, Gertz MA. Waldenstrom Macroglobulinemia. Blood. 2007 Feb 15; [Epub ahead of print].
Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr. Waldenstroms macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer. 1998;82(6):1078–81.
Linet MS, Humphrey RL, Mehl ES, Brown LM, Pottern LM, Bias WB, McCaffrey L Acase-control and family study ofWaldenstroms macroglobulinemia. Leukemia. 1993;7(9):1363–9.
Williamson LM, Greaves M, Waters JR, Harling CC. Waldenstroms macroglobuli-naemia: three cases in shoe repairers. BMJ. 1989;298:498–9.
Travis LB, Li CY, Zhang ZN, Li DG, Yin SN, Chow WH, et al. Hematopoietic malignancies and related disorders among benzene-exposed workers in China. Leuk Lymphoma. 1994;14:91–102.
Fine JM, Muller JY, Rochu D, Marneux M, Gorin NC, Fine A, Lambin P. Waldenstroms macroglobulinemia in monozygotic twins. Acta Med Scand. 1986;220(4):369–73.
Renier G, Ifrah N, Chevailler A, Saint-Andre JP, Boasson M, Hurez D. Four brothers with Waldenstrom's macroglobulinemia. Cancer. 1989;64(7):1554–9.
McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol 2003;30(2):146–52.
Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Ditzel Santos1 D Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson1 CJ, Manning R, Branagan AR, Morton CC. Characterization of familial Waldenström's macroglobulinemia. Ann Oncol. 2006;17(3):488–94.
Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/Waldenstroms macroglob ulinemia: an evolving concept. Adv Anat Pathol. 2005;12(5):246–55.
Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.
Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:132–4.
Owen RG, Barrans SL, Richards SJ, O'Connor SJ, Child JA, Parapia LA, Morgan GJ, Jack AS. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116(3):420–8.
San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:187–95.
KonoplevS,MedeirosLJ,Bueso-RamosCE,JorgensenJL,LinP. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol. 2005;124(3):414–20.
Owen RG, Hillmen P, Rawstron AC, et al. CD52 expression in Waldenström's mac roglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma. 2005;5:278–81.
Offit K, Parsa NZ, Filippa D, et al. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood. 1992;80:2594–9.
Iida S, Rao PH, Ueda R, et al. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leuk Lymphoma. 1999;34:25–33.
Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, Lai R, Glassman A, Bueso-Ramos CE. Cytogenetic findings in lymphoplasmacytic lym phoma/Waldenstroms macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116(4):543–9.
Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, Jalal SM, Qi Y, Kyle RA, Greipp PR, Fonseca R. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100(8):2996–3001.
Liu YC, Miyazawa K, Sashida G, Kodama A, Ohyashiki K. Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogen-esis of 20q11 anomaly. Cancer Genet Cytogenet. 2006;169:69–72.
Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, Garcia-Sanz R, Moro MJ, Aguilera C, Hernandez J, Xu R, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalez-Paz N, Gertz MA, San Miguel JF, Fonseca R. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136(1):80–6.
Chang WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108(8):2755–63. Epub 2006 Jun 27.
Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin 6 in human multiple myeloma. Blood. 1995;85:863–72.
Hatzimichael EC, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobuline mia. Eur J Haematol. 2001;66:1–6.
Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001;2:1103–8.
Hunter Z, Leleu X, Hatjiharissi E, Santos D, Xu L, Ho A, et al. IgA and IgG hypogam-maglobulinemia are associated with mutations in the APRIL/BLYS receptor TACI in Waldenström's. Blood. (ASH Annual Meeting Abstracts) 2006;108:Abstract 228.
Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, et al. B-lym phocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia. Blood. 2006;107:2882–8. Epub 2005 Nov 22.
Adamia S, Crainie M, Kriangkum J, Mant MJ, Belch AR, Pilarski LM. Abnormal expression of hyaluronan synthases in patients with Waldenström's macroglob ulinemia. Semin Oncol. 2003;30:165–8.
Adamia S, Treon SP, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, et al Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenström's macroglobulinemia. Clin Lymphoma. 2005;5:253–6.
Kriangkum J, Taylor BJ, Reiman T, et al. Origins of Waldenstroms macroglob ulinemia: does it arise from an unusual B-cell precursor ? Clin Lymphoma. 2005;5:217–9.
Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc. 1987;62(8):719–31.
Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006;145:435–47.
Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. Curr Opin Hematol. 2004;11(6):411–8.
Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman S R, Roy V Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82(3):323–41.
Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori infection and gastric lym phoma. N Engl J Med. 1994;330(18):1267–71.
Ocio EM, Hernandez JM, Mateo G, Sanchez ML, Gonzalez B, Vidriales B, Gutierrez NC, Orfao A, San Miguel JF. Immunophenotypic and cytogenetic comparison of Waldenstroms macroglobulinemia with splenic marginal zone lym phoma. Clin Lymphoma. 2005;5(4):241–5.
Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstroms macr oglob ulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214–26.
Dimopoulos MA, Alexanian R. Waldenstroms macroglobulinemia. Blood. 83:1452–9.
Fudenberg HH, Virella G. Multiple myeloma and Waldenstroms macroglobuline mia: unusual presentations. Semin Hematol. 1980;17(1):63–79. Review
Lin P, Buesco-Ramos C, Wilson CS, et al. Waldenstrom macroglobulinemia involving extramedullary sites. Am J Surg Pathol. 2003;27:1104–13.
Fadil A, Taylor DE. The lung and Waldenstroms macroglobulinemia. South Med J. 1998;91:681–5.
Oveliama J, Friedman AH. Ocular manifestations of multiple myeloma, Waldenstroms macroglobulinemia and benign monoclonal gammopathy. Surv Ophthalmol. 1981;26:157–69.
Civit T, Coulbois S, Baylac F, et al. Waldenstroms macroglobulinemia and cerebral lymphoplasmacytic proliferation: Bing and Neel syndrome—Apropos of a new case. Neurochirurgie. 1997;43:245–9.
Schnitzler L, Schubert B, Boasson M, Gardais J, Tourmen A. Urticaire chronique, lésions osseuses, macroglobulinémie IgM: maladie de Waldenström? Bull Soc Fr Derm Syph. 1974;81:363–7.
Rosenthal JA, Curran WJ Jr, Schuster SJ. Waldenström's macroglobulinemia resulting from localized gastric lymphoplasmacytoid lymphoma. Am J Hematol. 1998;58:244–5.
Dimopoulos MA, Galani E, Matsouka C. Waldenstroms macroglobulinemia., Hematol Oncol Clin North Am. 1999;13(6):1351–66.
Dimopoulos MA, Kyle RA, AnagnostopoulosA, and Treon SP. Diagnosis and Management of Waldenstrom's Macroglobulinemia. J Clin Oncol. 2005;23(7):1564–77.
Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med. 1995;10:128–41.
Farhangi M, Merlini G. The clinical implications of monoclonal immunoglobulins. Semin Oncol. 1986;13:366–79.
Libow LF, Mawhinney JP, Bessinger GT. Cutaneous Waldenstrom's macroglob ulinemia: report of a case and overview of the spectrum of cutaneous disease. Am Acad Dermatol. 2001;45(6 Suppl):S202–6.
Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, Cohen AM. Waldenstrom's mac roglobulinemia associated with AA amyloidosis. Int J Hematol. 2001;74(1):76–8.
Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglob ulinemia. J Clin Oncol. 1993;11:914–20.
Baldini L, Nobile-Orazio E, Guffanti A, Barbieri S, Carpo M, Cro L,. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenström's macroglobuline mia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol. 1994;45:25–31.
Kwan JY. Paraproteinemic neuropathy. Neurol Clin. 2007;25(1):47–69.
Dalakas MC, Flaum MA, Rick M, : Treatment of polyneuropathy in Waldenstrom's macroglobulinemia: role of paraproteinemia and immunologic studies. Neurology. 1983;33:1406–10.
Bryce AH, Kyle RA, Dispenzieri A, Gertz MA. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol. 2006;81(7):511–8.
Lindstrom FD, Hed J, Enestrom S. Renal pathology of Waldenstrom's macroglob ulinemia with monoclonal antiglomerular antibodies and nephritic syndrome. Clin Exp Immunol. 1980;41:196–204.
Sen HN, Chan CC, Caruso RC, et al. Waldenstrom's macroglobulinemia-associ ated retinopathy. Ophthalmology. 2004;111:535–9.
Bradley JR, Thiru S, Bajallan N, Evans DB. Renal transplantation in Waldenstrom's macroglobulinaemia. Nephrol Dial Transplant. 1988;2:214–6.
Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):206–10.
Gobbi PJ, Bettini R, Montecucco C, et al. Study of Prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939–45.
Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000 ; 96:852–8.
Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, Wolf RC, Hoffmann RJ, Lust JA, Witzig TE, Lacy MQ, Dispenzieri A, Vincent Rajkumar S, Zeldenrust SR, Greipp PR, Kyle RA. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom mac roglobulinaemia. Br J Haematol. 2006;133(2):158–64.
Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel recommendation from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:127–31.
Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenström's macroglobulinemia. J Clin Oncol. 2005;23(7):1564–77.
Kaplan AA. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. Ther Apher. 2001;5:171–5.
Zarkovic M, Kwaan HC. Correction of hyperviscosity by apheresis. Semin Thromb Hemost. 2003;29:535–42.
Humphrey JS, Conley CL. Durable complete remission of macroglobulinemia after splenectomy: a report of two cases and review of the literature. Am J Hematol. 1995;48(4):262–6.
Takemori N, Hirai K, Onodera R, Kimura S, Katagiri M. Durable remission after splenectomy for Waldenstrom's macroglobulinemia with massive splenomegaly in leukemic phase. Leuk Lymphoma. 1997;26(3–4):387–93.
Kyle, RA, Greipp, PR, Gertz, MA, et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108:737.
Annibali O, Petrucci MT, Martini V, Tirindelli MC, Levi A, Fossati C, Del Bianco P, Mandelli F, Foa R, Avvisati G. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and pred nisone: results and cost analysis. Cancer. 2005;103(3):582–7.
Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98(1):41–8.
Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol. 2003;30(2):220–5.
Leblond V, Levy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, Remenieras L, Porcher R, Gardembas M, Marit G, Deconinck E, Desablens B, Guilhot F, Philippe G, Stamatoullas A, Guibon O; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001;98(9):2640–4.
Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2005;6(2):136–9.
Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstrom's (12):2694–8.
Fridrik MA, Jager G, Baldinger C, et al. First-line treatment of Waldenstrom's disease with cladribine. Ann Hematol. 1997;74:7–10.
Hellmann A, Lewandowski K, Zauche JM. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol. 1999;63:35–41.
Delannoy A, Van de Neste E, Michaux JL, et al. Cladribine for Waldenstrom's macroglobulinemia. Br J Haematol. 1999;104:933–4.
Hampshire A, Saven A: update of bolus administration of cladribine in the treatment of Waldenstrom's macroglobulinemia. Blood. 2003;102:402a, (abstr).
Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin/cyclo-phosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's Macroglobulinemia /lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma. 2005;6(2):131–5.
Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant. 2006;12(8):845–54.
Desikan R, Dhodapkar M, Siegel D, et al. High-dose therapy with autologous hae mopoietic stem cell support for Waldenstrom's macroglobulinemia. Br J Haematol. 1999;105:993–6.
Anagnostopoulos A, Dimopoulos MA, Aleman A, et al. High-dose chemotherapy followed by stem-cell transplantation in patients with resistant Waldenstrom's mac roglobulinemia. Bone Marrow Transplant. 2001;27:1027–9.
Toumilhac O, Leblond V, Tabrizi R, et al. Transplantation in Waldenstrom's mac roglobulinemia: the French experience. Semin Oncol. 2003;30:291–6.
Dreger P, Stilgenbauers S, Seyfarth B, et al. Autologous and allogeneic stem cell transplantation for treatment of Waldenstrom's macroglobulinemia, 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 70.
Fassas A, Dhodapkar M, Mc Coy J, et al. Management of Waldenstrom's mac roglobulinemia in the pre-rituximab era: update on US Intergroup Trial 59003 and the Arkansas autotransplant experience, 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October, 2004, p 59.
Maloney DG, Sandmaier BM, Maris M, et al. Allogeneic hematopoietic cell transplantation for refractory Waldenstrom's macroglobulinemia: replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood. 2003;102:472b, (abstr).
Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23(3):474–81.
Dimopoulos MA, Zervas C Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenstroms macroglobulinemia with rituximab. J Clin Oncol. 2002;20(9):2327–33.
Weng WK, Levy R. Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–47.
Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23(3):474–81.
Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's mac-roglobulinemia with rituximab. J Clin Oncol. 2002;20:2327–33.
Dimopoulos MA, Zervas K, Zomas A, et al. Treatment of Waldenstrom's mac roglobulinemia with rituximab: prognostic factors for responses and progression. Leuk Lymphoma. 2004;45:2057–61.
Treon P, Emmanoullides CA, Kimby E, et al: Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol. 2005;16:132–8.
Ghobrial IM, Fonseca R, Greipp PR, et al. The initial “flare” of IgM level after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia. An Eastern Cooperative Oncology Group Study. Blood. 2003;102:448a, (abstr).
Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004;15:1481–3.
Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol. 2004;77(4):329–30.
Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005;5(4):273–7.
Treon SP, Branagan A, Wasi P, et al. Combination therapy with rituximab and fludarabine in Waldenstrom's macroglobulinemia. 3rd International Workshop on Waldenstrom's Macroglobulinemia, Paris, France, October 2004, p 27.
Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom's mac roglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma. 2005;5(4):278–81.
Owen RG, Rawstron AC, Osterborg A, et al. Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia. Blood. 2003;102:644a, (abstr).
Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom's mac roglobulinemia with thalidomide. J Clin Oncol. 2001;19:3596–601.
Coleman M, Leonard J, Lyona L, et al. Treatment of Waldenstrom's macroglob ulinemia with clarithromycin, low-dose thalidomide and dexamethasone. Semin Oncol. 2003;30:270–4.
Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom's mac roglobulinemia with single-agent thalidomide or with the combination of clari thromycin, thalidomide and dexamethasone. Semin Oncol. 2003;30:265–9.
Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570–5. Epub 2007 Mar 12.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A Pangalis GA. Treatment of relapsed or refractory Waldenstrom's macroglobuline mia with bortezomib. Haematologica. 2005;90(12):1655–8.
Frankel S. Oblimersen sodium (G 3139 Bcl–2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:300–4.
Treon SP, Tourmihac O, Branagan AR, et al. Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2004;5:205–7.
Patterson CJ, Soumerai J, Hunter Z, Leleu X, Ghobrial I, Treon SP. Sildenafil citrate suppresses disease progression in patients with Waldenström's macroglob ulinemia [abstract]. J Clin Oncol. 2006;24(18 Suppl):435S.
Porrata LF, Markovic SN. Androgenic therapy for Waldenstrom's macroglob ulinemia. Am J Hematol. 2006;81(11):892–3.
Tsai DE, Maillard I, Downs LH, Alavi A, Nasta SD, Glatstein E, Schuster SJ. Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2004;45(3):591–5.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Simpson, L., Gertz, M. (2008). Waldenstrom's Macroglobulinemia. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_32
Download citation
DOI: https://doi.org/10.1007/978-1-59745-564-0_32
Publisher Name: Humana Press
Print ISBN: 978-1-934115-82-4
Online ISBN: 978-1-59745-564-0
eBook Packages: MedicineMedicine (R0)